Process Control, Automation, and PAT

New and existing technologies, as well as a patient-centric focus, are pushing drug formulation into exciting directions.

New technologies improve efficiency and remove operator intervention.

Manual and automated inspection technologies have their own advantages and limitations.

The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk.

Leveraging automation advancements can help improve efficiency in aseptic processing and speed up commercialization of critical drug products.

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

Lonza’s Joe Garrity and Jerry Jiang discuss the importance of not only automating CGT manufacturing, but also standardizing across processes.

Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

Digital transformation is allowing for better handling, analysis, and protection of vast data collection.

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.

Effective analytics will eliminate failures, deviations, and non-conformances.

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.

Digital transformation allows for smarter and connected biomanufacturing operations.

Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.

Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, reviews the company’s latest moves in targeting automation.

As new analytical technologies advance, insight into the twin-screw granulation process is growing.

SCHOTT now offers ViewCell, a new component meant to add flexibility to biopharmaceutical process control.

A new generation of interactive formulation development platforms can leave trial and error in the formulation process in the past.

EMS is a leader in the cleanroom industry, delivering complete cleanroom monitoring and control solutions, services to customers, and ensuring quality by design from inception to process control.

FDA is anticipating how AI may advance manufacturing and improve supply chain security.

Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.

Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.

Manufacturers face the challenge of meeting growing demand for personalized biopharmaceuticals.

The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.

The results found that repeatability testing found all 15 processes to be with in specification for target final concentration.

Monil Malhotra, vice-president of Industrial Software at Emerson, discusses the growing demand for software solutions in the pharma industry.

Claudio Fayad, VP of Technology, Process Systems, and Solutions discusses the intersection of automation and data security in the pharma industry.